Drug Trial Radar · NCT03244072
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60,000
Planned (sponsor's estimate)
Start
Jun 1, 2027
Primary completion
Oct 2030
Study completion Oct 2031
Sponsor
- Lead sponsor
- Jason Ahee, M.D.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
Conditions
- Endophthalmitis
Interventions
MoxifloxacinDrug
Intracameral injection
PlaceboDrug
intracameral injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endophthalmitis after cataract surgeryTime frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zion Eye Institute
St. George, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.